75.33
+1.52%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CanSino Biologics
Its shares trade on Shanghai under the ticker 688185.SS. It has been listed since 28 March 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.03bn and net income of CN¥27.2m. At that date it held total assets of CN¥7.18bn and shareholders' equity of CN¥4.96bn.
CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Mar 2019
- Employees
- 429
- Website
- cansinotech.com.cn ↗
Leadership
Pay as last reported
- Mr. Xuefeng YuChairman of the Board, Chief Executive Officer, General Manager, since 2009CN¥3.6m
- Mr. Shoubai ChaoChief Operating Officer, Deputy General Manager, Executive Director, since 2018CN¥2.6m
- Mr. Tao ZhuChief Scientific Officer, Deputy General Manager, since 2009CN¥2.7m
- Ms. Jing WangDeputy General Manager, Executive Director, Chief Commercial Officer, since 2017CN¥3.1m
- Mr. Dongxu QiuDeputy General Manager, since 2009CN¥2.1m
- Mr. Jin CuiSecretary of the BoardCN¥1.5m
- Mr. Zhicheng LiNon-Executive Director
- Mr. Yiu Leung CheungIndependent Non-Executive DirectorCN¥344,100
- Mr. Shuifa GuiIndependent Non-Executive DirectorCN¥300,000
- Mr. Jianzhong LiuIndependent Non-Executive DirectorCN¥300,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 99
- Social
- 99
- Governance
- 41
- Direct emissions (scope 1)
- 1,864.1 t
- Energy emissions (scope 2)
- 29,211.21 t
- Women in the workforce
- 51.4%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CanSino Biologics Inc has several strengths that contribute to their success. Firstly, the company has a strong research and development team, allowing them to innovate and develop breakthrough biopharmaceutical products. Additionally, CanSino has established strategic collaborations with reputable organizations, providing them with access to advanced technologies and expertise. Moreover, the company has a state-of-the-art manufacturing facility ensuring high-quality production. Lastly, CanSino has a diverse portfolio of vaccines targeting various diseases, helping them capture a wide market share.
Weaknesses
- Despite their strengths, CanSino Biologics Inc also faces a few weaknesses. One of the main weaknesses is their heavy reliance on a limited number of key suppliers for critical raw materials, which poses a supply chain risk. Furthermore, the company's heavy investment in research and development can lead to uncertainties in achieving timely returns on investment. Additionally, CanSino currently has a relatively small market presence compared to some of its competitors, reducing its brand recognition and market share.
Opportunities
- CanSino Biologics Inc has several opportunities that can fuel their growth in the market. The increasing demand for vaccines, especially amid global health crises, presents a significant opportunity for the company to expand its customer base and revenue. CanSino can also leverage its strong research and development capabilities to develop new and improved vaccines to address emerging diseases and unmet medical needs. Moreover, the growing prevalence of chronic diseases globally provides an opportunity for CanSino to develop vaccines and treatments in these areas.
Threats
- In addition to opportunities, CanSino Biologics Inc faces certain threats that could hinder their progress. One of the major threats is intense competition within the biopharmaceutical industry, where rivals are constantly vying for market share. This may lead to pricing pressures and reduced profitability. Moreover, stringent regulatory requirements and delays in obtaining necessary approvals can impact CanSino's product launch timelines. The company is also susceptible to global economic fluctuations and political instability, which may affect their international operations and market expansion efforts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.